An Efficacy and Safety Study of Gevokizumab in Treating Active Ulcers of Pyoderma Gangrenosum

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Pyoderma Gangrenosum

In brief

The study will evaluate the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosum (PG).

Key facts

Study ID

NCT02315417

Run by

XOMA (US) LLC

People needed

16

Starts

2014-11-01

Expected to finish

2016-03-01

Last updated by the study team

2016-04-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• A clinical diagnosis of classic pyoderma gangrenosum
• An active pyoderma gangrenosum ulcer
• Contraceptive measures adequate to prevent pregnancy during the study

You may not qualify if…

• Clinical evidence of acutely infected pyoderma gangrenosum
• History of allergic or anaphylactic reactions to monoclonal antibodies
• History of recurrent or chronic systemic infections
• Female subjects who are pregnant, planning to become pregnant, have recently delivered, or are breast-feeding
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Study site — Coral Gables, Florida, United States
• Study site — North Miami Beach, Florida, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — St Louis, Missouri, United States
• Study site — Lebanon, New Hampshire, United States
• Study site — New York, New York, United States
• Study site — Winston-Salem, North Carolina, United States
• Study site — Columbus, Ohio, United States
• Study site — Portland, Oregon, United States
• Study site — Philadelphia, Pennsylvania, United States
• Study site — Houston, Texas, United States
• Study site — Lubbock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.